The Impact of SARS-CoV-2 on the Human Immune System and Microbiome

Chuxi Wang¹, Xin Zhou², Meng Wang², Xin Chen¹,⁎

Abstract

A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the single-stranded enveloped RNA virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global pandemic, after it was first reported in Wuhan in December 2019. SARS-CoV-2 is an emerging virus, and little is known about the basic characteristics of this pathogen, the underlying mechanism of infection, and the potential treatments. The immune system has been known to be actively involved in viral infections. To facilitate the development of COVID-19 treatments, the understanding of immune regulation by this viral infection is urgently needed. This review describes the mechanisms of immune system involvement in viral infections and provides an overview of the dysregulation of immune responses in COVID-19 patients in recent studies. Furthermore, we emphasize the role of gut microbiota in regulating immunity and summarized the impact of SARS-CoV-2 infection on the composition of the microbiome. Overall, this review provides insights for understanding and developing preventive and therapeutic strategies by regulating the immune system and microbiota.

Keywords: COVID-19; SARS-CoV-2; immune system; microbiome

Introduction

Coronaviruses are RNA viruses that cause respiratory and intestinal infections in animals and humans. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new group of animal RNA viruses, is the pathogen responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic. On December 31, 2019, Chinese local hospitals and the Center for Disease Control and Prevention in China reported several cases of pneumonia with unknown etiology, and later found a seafood market in China’s Wuhan, Hubei Province as the primary location of the infection.¹,² The infecting pathogen was named 2019-novel coronavirus, which was later changed into SARS-CoV-2, and cases have been reported in 47 countries (Figure 1). On January 30, 2020, the World Health Organization declared the novel coronavirus outbreak as an “Emergency of International Concern” and announced it as pandemic on March 11, 2020.¹ Up to the end of July 15, 2020, SARS-CoV-2 caused over 15 million confirmed cases and 0.6 million confirmed deaths over the 216 countries,³ which led to huge public health concerns as well as economic burdens worldwide.

It has been suggested that immune responses may contribute to disease severity and progression. However, the mechanism of SARS-CoV-2 virus infection and the process of immune responses against SARS-CoV-2 are still unclear. Other factors that may interfere with immune responses, such as the microbiome, also require more attention. This article aimed to provide a review of current knowledge regarding SARS-CoV-2 on the immune system and how dysregulation of the immune response may contribute to the pathogenesis of COVID-19. Furthermore, we discussed the dysbiosis caused by the virus-related immune system disruption and provide insights into the therapeutic potentials of regulating the immune system and microbiota on the prevention, care management, and treatment of COVID-19.

SARS-CoV-2

According to the phylogenetic classification,⁵,⁶ SARS-CoV-2 belongs to the betacoronaviruses out of the four genera of coronaviruses, which includes the alphacoronaviruses, betacoronaviruses, gammacoronaviruses, and deltacoronaviruses.⁷ Coronaviruses are common pathogens of humans and animals. The word “corona” was named by a similar shape of the outside of the virus as the solar corona of the sun.⁸ Coronavirus is about 120 nanometers in diameter and is highly diverse. Common cold coronaviruses can cause upper respiratory tract infections in adults as well as diarrhea in infants and children.⁹

The known hosts for the former two genera are mammals whereas for the latter two are mostly avian.⁴ The genome structure of the coronavirus has been shown by the Zhang Lab.¹⁰ The genome of the coronavirus consists of (1) structural proteins, including envelope glycoproteins spike (S), envelope (E), membrane (M) and nucleocapsid (N), and (2) non-structure proteins (nsps), which are responsible for viral replication and host invasion.¹²
SARS-CoV-2 shares 88% identity with two bat-derived SARS-like coronaviruses, and about 76% identity with SARS-CoV, which was responsible for the outbreak of atypical pneumonia in 2003. Homology modeling demonstrated that SARS-CoV-2 and SARS-CoV share a similar receptor-binding domain, indicating that they may share the same receptor. Indeed, several groups have identified that the SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2) serves as the receptor for SARS-CoV-2. ACE2 is a transmembrane protein and shows high expression on various human tissues, including the small intestine, testis, heart, and lung. Blocking the virus entry is one of the common strategies for developing therapeutics against SARS-CoV-2. ACE2 is a transmembrane protein and shows high expression on various human tissues, including the small intestine, testis, heart, and lung. Blocking the virus entry is one of the common strategies for developing therapeutics against SARS-CoV-2.

The activation of innate immune responses involves the pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and nucleotide-binding receptors. PRRs can recognize the pathogen-associated molecular patterns (PAMPs) such as viral RNA and oxidized phospholipids. Once PRRs detect PAMPs, the intracellular signaling cascades will be activated, which leads to the secretion of antiviral effector molecules and elimination of the virus. Type I IFN then activates the Janus kinase-signal transducer and activator of transcription pathway. The adaptive immune system kicks in after the activation of the innate immune system. One of the major players, T cells, is responsible for the regulation of cellular immune responses and adaptive immune responses. The response time, target antigens, and the mechanism of viral antigen recognition vary between innate and adaptive immune response, and provide a dynamic and broad protection of the host.

The immune response against viral infections

An effective immune response can be defined as a biological reaction of the host’s body to the invasion of foreign substances (e.g., viral antigens). The immune responses include innate immune responses and adaptive immune responses. The response time, target antigens, and the mechanism of viral antigen recognition vary between innate and adaptive immune response, and provide a dynamic and broad protection of the host.

**The immune response against viral infections**

An effective immune response can be defined as a biological reaction of the host’s body to the invasion of foreign substances (e.g., viral antigens). The immune responses include innate immune responses and adaptive immune responses. The response time, target antigens, and the mechanism of viral antigen recognition vary between innate and adaptive immune response, and provide a dynamic and broad protection of the host.
neutralizing antibodies (NAbs) produced by B cells play a crucial role in restricting the virus life cycle. NAbs can function by binding to the virus particles and preventing its entry into the target cells or binding to the viral glycoprotein on the host cells to inhibit virus budding. On the other hand, the virus-specific antibody may facilitate the virus entering the host cells expressing Fc or complementary receptors by interacting with them and getting internalized, which is referred to as antibody-dependent enhancement (ADE). In short, because of the specificity and the immunological memory provided by the adaptive immune system, it is of vital importance that we understand the role it plays in SARS-CoV-2 infection in order to develop vaccines as well as treatments.

**The impact of SARS-CoV-2 on the innate immune system**

It is common to observe a dysregulation of the innate immune responses in COVID-19 patients. Upregulated IL-6, potentially produced by Mφ or monocytes, has been reported in COVID-19 patients in multiple studies. IL-6 is known to recruit immune mediators and can drive the cytokine release syndromes (CRS), which can cause local tissue damage and systemic non-protective inflammation. As CRS has been detected in SARS-CoV-2-infected patients, and it has been previously known to contribute to the morbidity in patients with SARS-CoV or MERS-CoV, clinical trials have been proposed and conducted on the blockade of IL-6 or its upstream activators, such as the blockade of GM-CSF, which activates myeloid cells and promotes the production as IL-6. Additionally, inflammatory cytokines and chemokines including IFNγ, MCP1, IP-10, TNF-α, and IL-10 are reported to be evaluated in COVID-19 patients. The pyroptosis marker lactate dehydrogenase is also reported to be evaluated in COVID-19 patients, and is thought to be an indicator for disease severity and mortality.

Although an activated innate immune response was observed in SARS-CoV-2-infected patients, their immune system failed to launch robust type I and type III IFN responses. The lack of IFN responses could potentially lead to deficiency in restricting the establishment of viral infection at early stages and contribute to the pathogenicity of COVID-19. An in vitro study indeed revealed that insufficient IFN responses result in higher virus loads in host cells and vice versa supplying exogenous type I IFN results in decreased virus titers in Vero cells infected with SARS-CoV-2. Interestingly, the virus receptor ACE2 has been reported as an interferon-stimulated gene that upregulates upon IFN I and II stimulation in the human airway epithelial cells, which adds complexity to the host-virus interaction. There are limited reports regarding the mechanisms underlying the inhibition of IFN responses by SARS-CoV-2. A few studies suggested that ORF6, ORF8, and nucleocapsid proteins potentially suppress the IFN production. Considering that

---

**Figure 2. The immune response against viral infections**. This figure shows how the immune system responds to viral infections. The PRRs from Mφ recognize PAMPs from the virus and release IFN and other cytokines. Mφ can potentially get infected and become Trojan horses. PPRs from Mφ and DC present viral antigens to T cells and B cells. Activated T cells produce pro-inflammatory and regulatory mediators, which kill infected cells. Activated B cells produce neutralizing virus particles to prevent the virus from cellular entry. DC: dendritic cell; IFN: interferon; Mφ: macrophage; PAMP: pathogen-associated molecular patterns; PPRs: pattern-recognition receptors.
SARS-CoV, which shares 76% similarity with SARS-CoV-2, encodes various IFN antagonists, including the structural proteins membrane and nucleocapsid, nonstructural proteins, Papain-Like Proteases, and accessory proteins, the potential antagonism of SARS-CoV-2 needs to be further investigated.

Despite its role in anti-viral immune responses, Mφ may be associated with the pathogenicity of COVID-19. Indeed, SARS-CoV-2 structural proteins are detectable in macrophages isolated from the spleen, lymph nodes, and lung tissue samples of COVID-19 patients and SARS-CoV-2 spike proteins can interact with macrophages. The susceptibility of Mφ to SARS-CoV-2 infection indicates that Mφ may serve as a potential viral reservoir and CD68+CD169+ Mφ have been detected to contain SARS-CoV-2 antigens during SARS-CoV-2 infection.

The impact of SARS-CoV-2 on the adaptive immune system

Humoral immunity plays a vital role in the host immune response against viruses. Particularly, the NAbS can potentially block the interaction between the SARS-CoV-2 spike protein and ACE2 on the cell membrane and thus prevent the entry of the virus. Antibody responses can be detected as early as the first week post symptom onset, and most patients show antibody responses within 2 weeks after symptom onset. Reports showed that immunoglobulin G (IgG) and immunoglobulin M (IgM) against SARS-CoV-2 nucleocapsid (NP) protein and membrane protein (M) have been detected in patients. Seroconversion for IgG and IgM are observed simultaneously or sequentially within 20 days post symptom onset, 6 days after which both IgG and IgM titers reach their plateau. IgG is found to persist longer compared to IgM and it is also widely observed in discharged patients. NAbs have been detected in patients within their third week after disease onset, and most of the discharged patients show persistent NAb titers. Of note, the titer of NAbs is found to be positively correlated with disease severity, and the correlation between NAb levels and the number of viral-specific T cell counts is significant. However, there are various levels of antibody responses between different patients, indicating the individual difference in immune responses to viral infection. Considering the similarity of SARS-CoV to SARS-CoV-2, cross-reactive NAbs have been reported by several groups. This is highly instructive for vaccine development.

While NAbs provide antiviral immunity, non-NAbs could enhance SARS-CoV-2 infection through ADE, which can induce sustained inflammation, lymphopenia, and CRS. Research on SARS-CoV showed that ADE contributes to the severity of the disease. Although ADE has not been well-studied in COVID-19 patients, there is a possibility that ADE could contribute to the disease progression.

Another aim of adaptive immunity is cellular immunity against viral infections, with CD4+ T cells releasing cytokines, which help B cells and cytotoxic T cells. After being activated, the CD8+ T cells eliminate the infected cells. T cell reactivity against SARS-CoV-2 can be detected about 1-week post symptom onset. Specific T cell reactions were detected against the S, M, NP as well as non-structural proteins. Similar to the antibody response, specific T cell reactivity against SARS-CoV-2 was detected in some unexposed healthy donors, indicating a potential cross-reactivity in some individuals.

Peripheral CD4+ and CD8+ T cell depletion has been observed in COVID-19 patients and especially in severe cases. For instance, IFNγ produced by CD4+ T cells is decreased in severe patients. The decrease of peripheral CD4+ and CD8+ T cells has also been reported in SARS-CoV infections and was related to the onset of disease. However, whether T cell depletion correlates with severity of COVID-19 needs to be further addressed. In addition, functional exhaustion of T cells has been reported in COVID-19 patients, indicated by the upregulation of exhaustion markers, including PD-1, CTLA-4, TIGIT, and TIM-3 and downregulation of IFN-γ, TNF-α, granzyme B, and IL-10. Of note, PD-1 is upregulated in both CD4+ and CD8+ T cell subsets in severe patients. A potential cause of the T cell exhaustion could be the inflammatory cytokines, such as IL-6, which is known to induce T cell exhaustion and has been shown to be elevated in COVID-19 patients. Taking together, targeting T cell depletion and exhaustion may help to provide appropriate immunity and bring therapeutic benefits in terms of fighting SARS-CoV-2 infection.

Role of microbiota in innate and adaptive immunity and SARS-CoV-2 infection

Microbiota consists of various microorganisms, including bacteria, viruses, fungi, and protozoa. They have been found in high density in the intestine and closely regulate homeostasis of the innate and adaptive immune system. Gut microbiota provides signals to adjust the immune cells for inducing or repressing an immune response. Such signals are essential for functional activation of the immune system under certain circumstances. For example, germ-free mice showed impaired development of lymphocytes and failed to sustain production of proinflammatory cytokines after repeated TLR stimulation. Therefore, attention has been drawn on how the microbiome is interacting with the immune system, and how we can modulate such interactions.

A functional antiviral immune response requires the participation of microbiota. Antibiotics-treated mice are unable to generate robust antibody response against influenza infection. Also, the absence of TLR3 recognizing flagellin from bacteria leads to reduced antibody production post viral infection. Such findings imply that, for B cells to produce healthy antibodies against viral infections, the microbiome is required. The underlying mechanism of such relationship might be explained by a recent study that showed that selection and diversity of the B cell repertoire is regulated by microbiota, and this regulation might be species-specific, as indicated by another multi-omics study. On the other hand, an important cause of COVID-19 related deaths is secondary respiratory bacterial infections, and there are evidences that microbiome immune interactions are regulating such secondary infections. Therefore, we believe that the microbiota is an essential component that not only regulates the antiviral immune response, but also closely affects the disease outcome.

Role of microbiota in functions of innate immunity

Gut commensal microorganisms are normally colonizing the mucous layer of the small and large intestines, which are formatted by specialized epithelial cells and create a physical barrier for the microbiota. A change of the components or injuries of the layer would let the microbiota enter the intestinal lamina propria through an opening of the barrier or by uptake by
Mφ, DCs, or M cells. DCs or Mφ patrolling epithelia of barrier organs would recognize the microbial or pathogen-associated molecular patterns (MAMPs or PAMPs) from bacteria by their surface PRRs and then the phagocytosis process begins.26

There are different MAMPs or PAMPs from bacteria that have been identified affecting the differentiation and function of lymphoid lineage innate cells in various mechanisms.62 One type of MAMPs is from the microbial components, which act as ligands that can initiate PRR signaling. For example, bacterial flagellin can induce nucleotide-binding receptor signaling through recognition of TLR-5 signaling.72,73 Another type of MAMPs are the microbiota-derived products/metabolites, such as short chain fatty acids (SCFAs),74 and interestingly certain bacteria appear to be major producers of SCFAs. For example, Faecalibacterium prausnitzii is responsible for the majority of butyrate production.75 These SCFAs affect the activation of innate cells and signaling by inhibiting histone deacetylation.76

Despite the important role of microbiota in regulating innate immunity, several studies have provided evidences that the microbiota tunes the functions of the adaptive immune response. One of the underlying mechanisms is through activated Mφ and DCs carrying engulfed bacteria or epithelium-adhering bacteria to draining lymph nodes, where they initiate the differentiation of naïve CD4+ T cells into specialized T cells such as IL-17+CD4+ (Th17) cells.77 Th17 cells are dominated in the lamina propria of the small intestine (30%–40% of differentiated memory CD4+ T cells78), but were absent in germ-free mice or mice treated with antibiotics. Certain species of bacteria were reported to induce differentiation to Th17 cells, including segmented filamentous bacteria (SFB)79 and Bifidobacterium adolescentis.80 Regulatory T cells are mucosal related T cells in the intestine and are known to maintain commensal tolerance.81,82 The development and IL-10 secretion of regulatory T cells is influenced by commensal bacteria Bacteroides fragilis, via microbial product polysaccharide A.83 Therefore, the composition of the intestinal microbiota regulates the balance between Th17 and Treg cells, and influences mucosal immunity and the susceptibility to mucosal related diseases such as bowel diseases.78,79

Microbiota also talks to the host through unconventional T cells, invariant natural killer T cells, and mucosal-associated invariant T cells. They are less common compared to conventional T cells, but highly abundant in the gut mucosa. These unconventional T cells encode different T cell receptors and recognize antigens that may not be recognized by conventional T cells. Invariant natural killer T cells respond to glycolipid antigen and phospholipids,84 whereas mucosal-associated invariant T cells recognize riboflavin (vitamin B2) metabolic derivatives.85 These unconventional T cells add another layer of complexity to the relationship between microbiota and host immunity.

Humoral mucosal immunity is also affected by microbiota as germ-free mice showed a reduced IgA response, which could be restored rapidly by microbial colonization.8 Gut microbiota are required for a functional B cells in marginal zone66 and can directly regulate B cell activation and differentiation.87 In addition, the process of class switch recombination can also be affected by microbiota.88

**Changes in the microbiota during SARS-CoV-2 infection**

There are evidences suggesting that the gut microbiota affects pulmonary health through gut-lung cross talk.89 Such crosstalk is bidirectional, which means microbial products/metabolites can influence the homeostasis of the lung, and the pathology of the lung would also affect the gut microbiota.90 Several studies identified the presence of lung microbiota and revealed a distinct microbiome that was relevant to the chronic progression of lung diseases.91 Understanding such crosstalk will provide important knowledge on the role of microbiota regarding viral infection and host defenses.

Although it is widely known that viral infection could affect the gut microbiome,92 the number of current studies on determination of the changes in composition of microbiota in COVID-19 patients is limited. COVID-19 infection is associated with acute respiratory distress syndrome,93 for which microbiota is surely involved in disease progression.94 Also, it has been confirmed that SARS-CoV-2 could infect gut tissue,95 and viral RNA was detected in COVID-19 patient fecal samples.96 More direct measurements of gut microbiota composition showed that gut microbial communities were significantly changed in COVID-19 patients compared to healthy controls.97 One study pointed out that the abundance of the Ruminococcaceae family and several genera from the Lachnospiraceae family were dramatically reduced in COVID-19 patients. Also, compared to H1N1 patients, COVID-19 patients had a unique gut microbiota signature, suggesting potential biomarkers for COVID-19 infection and potential targets for future therapy. Another study linked the anti-inflammatory bacteria F. prausnitzii to be negatively correlated with disease severity. Several studies pointed out the increase of opportunistic pathogens in gut microbiota post SARS-CoV-2 infections,98 which are proposed to be the cause or complications for gut related disorders, such as inflammatory bowel disease.99 Several insights already pointed out the potential mechanisms underlying this gut-lung axis signal cross-talking in COVID-19 patients,100 including the modulation of the immune system through SCFA,101 or mitochondrial oxidative stress related dysbiosis.102 Of note, one review pointed out the age-related dysbiosis might worsen the disease outcome of COVID-19 patients.103 In summary, understanding the role of microbiota will not only help understanding the SARS-CoV-2 infection process, but also provide guidance on disease treatment, such as the use of probiotics.104

**Conclusions**

SARS-CoV-2 has become a global threat to health and economics. The immune response in SARS-CoV-2 infection plays an important role and significant dysregulation of innate and adaptive immune responses may contribute to disease severity and progression. However, the mechanism of interaction between virus infection and immune response regulation and the relationship of immune response to other medical complications (eg, health and lung failure) are still unclear. In addition, other factors that may regulate immune response and disease onset such as microbiome need further investigation. In this review, we focus on the current knowledge regarding how the immune system reacts after SARS-CoV-2 infection, and emphasize the importance of understanding the role of microbiota in this infection process. We hope this review will provide information and guidance for future research related to the understanding and treatment of COVID-19 patients.

**References**

[1] Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis 2020;94:44-48.
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. *Int J Infect Dis* 2005;9(6):323–330.

Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. *Cell Mol Immunol* 2020;17(5):541–543.

He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. *Int J Infect Dis* 2005;9(6):323–330.

Singh N, Thangaraju M, Prasad PD, et al. Identification species of symbiotic bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. *Proc Natl Acad Sci U S A* 2016;113(50):E8141–E8150.

Cebula A, Servewyn M, Rempala GA, et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. *Nature* 2013;497(7448):258–262.

Tan C, Dong E, Gava-Zanorsky N, et al. Blockade of dendritic cell and their subsets. *Cell Mol Immunol* 2020;17(5):541–543.
[103] Viana SD, Nunes S, Reis F. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - role of gut microbiota dysbiosis. *Ageing Res Rev* 2020;62:101123.

[104] Giannoni E, Baud D, Agri VD, Gibson GR, Reid G. Probiotics and COVID-19. *Lancet Gastroenterol Hepatol* 2020;5(8):720–721.

[105] American Journal of Managed Care. A Timeline of COVID-19 Developments in 2020. Published 2020. Available from: https://www.ajmc.com/view/a-timeline-of-covid19-developments-in-2020. Updated July 3, 2020. Accessed November 4, 2020.

[106] World Health Organization. Timeline of WHO’s Response to COVID-19. Published 2020. Available from: https://www.who.int/news/item/29-06-2020-covidtimeline. Updated September 9, 2020. Accessed November 06, 2020.

How to cite this article: Wang C, Zhou X, Wang M, Chen X. The impact of SARS-CoV-2 on the human immune system and microbiome. *Infect Microb Dis* 2021;3(1):14–21. doi: 10.1097/IM9.0000000000000045